Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Transposagen Biopharmaceuticals Inc.

www.transposagenbio.com

Latest From Transposagen Biopharmaceuticals Inc.

Gilead Partners With Sangamo For Gene Editing As It Builds Up Kite's Cell Therapy Platform

Gilead committed more than $3bn via its subsidiary Kite to license Sangamo's zinc finger technology for gene editing that may deliver improved T cell therapies for cancer. More deals are expected in this space as Gilead builds its cell therapy platform after buying Kite last year.
Deals Business Strategies

Gene Editing: Rewriting The Code

Gene editing technologies, which enable knockout or modification of specific genes, could get first use in modifying T cells to fight cancer and HIV, but its long-term potential to control gene expression in vivo has sparked Series A financings of three start-ups in the past 18 months.

BioPharmaceutical
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
    • Gene Therapy, Cell Therapy
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Transposagen Biopharmaceuticals Inc.
  • Senior Management
  • Eric Ostertag, MD, PhD, Pres. & CEO
  • Contact Info
  • Transposagen Biopharmaceuticals Inc.
    Phone: (859) 428-8561
    Lexington, KY
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register